12:00 AM
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Osphena ospemifene regulatory update

FDA approved an NDA from Shionogi for Osphena ospemifene to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal atrophy. The drug's label includes a boxed warning that it can cause endometrial thickening and an increased...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >